NLRP3 and multiple sclerosis: Itaconate and fumarate derivatives also inhibited NLRP3 activation induced by lysophosphatidylcholine (LPC), a lipid molecule used to induce demyelination in models of multiple sclerosis [31, 32, 33], further highlighting a potential mechanism of DMF action in multiple sclerosis treatment.